The systematic study of the influence of neutron excess on the fusion cross sections using different proximity-type potentials

Using different types of proximity potentials, we have examined the trend of variations of barrier characteristics (barrier height and its position) as well as fusion cross sections for 50 isotopic systems including various collisions of C, O, Mg, Si, S, Ca, Ar, Ti and Ni nuclei with $1\leq N/Z < 1.6$ condition for compound systems. The results of our studies reveal that the relationships between increase of barrier positions and decrease of barrier heights are both linear with increase of $N/Z$ ratio. Moreover, fusion cross sections also enhance linearly with increase of this ratio.Comment: 28 pages, 7 figures, 5 Table

Mucoadhesive bilayer tablets for buccal delivery of carvedilol: in vitro and in vivo investigations.

Se diseñó un sistema mucoadherente bicapa de carvedilol para administración bucal, con el objetivo de mejorar la biodisponibilidad y conseguir una liberación sostenida. Como portadores se utilizaron Carbopol 934P e hidroxipropilmetilcelulosa K4M, y las formulaciones obtenidas se sometieron a estudios de pH superfi cial, índice de expansión y bioadhesión y liberación de fármaco in vitro. Se analizó la cinética de los datos de liberación de fármaco in vitro, mediante ajuste en modelos de orden cero, primer orden, Higuchi, Hixson-Crowell y Korsmeyer Peppas. El estudio del rendimiento farmacocinético in vivo del lote optimizado se realizó en conejos. Los datos obtenidos de la optimización y evaluación del sistema revelaron que las formulaciones presentaban índices de expansión y parámetros tecnológicos satisfactorios. La formulación F5 presentó el mayor grado de bioadherencia (3.5 ± 0.6 N) y su retención en la mucosa bucal porcina fue de 7 h. El ajuste al modelo de los datos de liberación in vitro demostró que seguían un patrón de liberación de orden cero con un comportamiento de liberación no Fickian, es decir, con valores de n entre 0.71 y 1.17, lo que indica que la liberación fue una combinación de erosión del comprimido y difusión desde la matriz. Los valores farmacocinéticos obtenidos presentaron una diferencia signifi cativa entre Cmax, Tmax y los valores del área bajo la curva de las formulaciones bucal y oral, es decir, un aumento de la biodisponibilidad en los comprimidos bucales en comparación con la formulación oral. Las curvas de concentración en plasma de los comprimidos bucales evidenciaron claramente un comportamiento de liberación sostenido.Mucoadhesive bilayered system of carvedilol was designed for buccal application with the objective of improving bioavailability and producing sustained release. Carbopol 934P and hydroxypropylmethylcellulose K4M were employed as carriers and the developed formulations were subjected for evaluation of surface pH, swelling index, in vitro bioadhesion and in vitro drug release studies. In vitro drug release data was analyzed for release kinetics by fi tting into Zero order, First order, Higuchi, Hixson-Crowell and Korsmeyer Peppas models. In vivo pharmacokinetic performance of the optimized batch was investigated in rabbits. Data emerged from optimization and evaluation of the system revealed that formulations exhibited satisfactory technological parameters and swelling indices. Formulation F5 showed maximum bioadhesion (3.5 ± 0.6 N) and was found to be retained for 7 h on porcine buccal mucosa. The model fi tting of in vitro release data demonstrated that it followed zero order release pattern with non-fi ckian release behavior i.e. n values ranging from 0.71 to 1.17, indicating the release was combination of tablet erosion and diffusion from the matrix. The obtained pharmacokinetic values showed signifi cant difference between Cmax, Tmax and area under curve values of oral and buccal formulation, i.e. increase in bioavailability of buccal tablet as compared with oral formulation. Plasma concentration curves for the buccal tablet clearly showed evidence of sustained release behavio

IoMT Tsukamoto Type-2 fuzzy expert system for tuberculosis and Alzheimer’s disease

Accurate disease monitoring is an extremely time-consuming task for medical experts and technocrats involved, requiring technical support for diagnostic systems. To overcome this situation, we developed an Internet of Medical Things (IoMT) based on Tsukamoto Type 2 Fuzzy Inference System (TT2FIS) that can easily handle diagnostic and predictive aspects in the medical field. In the proposed system, we developed a Tsukamoto type 2 fuzzy inference system that takes the patient’s symptoms as input factors and the medical device as the output factor of the result. The aim of this work is to demonstrate the usefulness of type 2 fuzzy sets in Tuberculosis and Alzheimer’s disease diagnostic system. Numerical calculations are also performed to illustrate the applicability of the proposed method. A validation of the proposed derivation of the proposed IoMT model is also discussed in the results and conclusions section

Impact of COVID-19 on heart failure hospitalization and outcome in India – A cardiological society of India study (CSI–HF in COVID 19 times study – “The COVID C–HF study”)

Objectives: The presentation and outcomes of acute decompensated heart failure (ADHF) during COVID times (June 2020 to Dec 2020) were compared with the historical control during the same period in 2019. Methods: Data of 4806 consecutive patients of acute HF admitted in 22 centres in the country were collected during this period. The admission patterns, aetiology, outcomes, prescription of guideline-directed medical therapy (GDMT) and interventions were analysed in this retrospective study. Results: Admissions for acute heart failure during the pandemic period in 2020 decreased by 20% compared to the corresponding six-month period in 2019, with numbers dropping from 2675 to 2131. However, no difference in the epidemiology was seen. The mean age of presentation in 2019 was 61.75 (±13.7) years, and 59.97 (±14.6) years in 2020. There was a significant decrease in the mean age of presentation (p = 0.001). Also. the proportion of male patients decreased significantly from 68.67% to 65.84% (p = 0.037). The in-hospital mortality for acute heart failure did not differ significantly between 2019 and 2020 (4.19% and 4.,97%) respectively (p = 0.19). The proportion of patients with HFrEF did not change in 2020 compared to 2019 (76.82% vs 75.74%, respectively). The average duration of hospital stay was 6.5 days. Conclusion: The outcomes of ADHF patients admitted during the Covid pandemic did not differ significantly. The length of hospital stay remained the same. The study highlighted the sub-optimal use of GDMT, though slightly improving over the last few years

Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry

Aims: Hypertensive disorders occur in women with peripartum cardiomyopathy (PPCM). How often hypertensive disorders co-exist, and to what extent they impact outcomes, is less clear. We describe differences in phenotype and outcomes in women with PPCM with and without hypertensive disorders during pregnancy. Methods: The European Society of Cardiology PPCM Registry enrolled women with PPCM from 2012-2018. Three groups were examined: 1) women without hypertension (‘PPCM-noHTN’); 2) women with hypertension but without pre-eclampsia (‘PPCM-HTN’); 3) women with pre-eclampsia (‘PPCM-PE’). Maternal (6-month) and neonatal outcomes were compared. Results: Of 735 women included, 452 (61.5%) had PPCM-noHTN, 99 (13.5%) had PPCM-HTN and 184 (25.0%) had PPCM-PE. Compared to women with PPCM-noHTN, women with PPCM-PE had more severe symptoms (NYHA IV in 44.4% and 29.9%, p&lt;0.001), more frequent signs of heart failure (pulmonary rales in 70.7% and 55.4%, p=0.002), higher baseline LVEF (32.7% and 30.7%, p=0.005) and smaller left ventricular end diastolic diameter (57.4mm [±6.7] and 59.8mm [±8.1], p&lt;0.001). There were no differences in the frequencies of death from any cause, re-hospitalization for any cause, stroke, or thromboembolic events. Compared to women with PPCM-noHTN, women with PPCM-PE had a greater likelihood of left ventricular recovery (LVEF≥50%) (adjusted OR 2.08 95% CI 1.21-3.57) and an adverse neonatal outcome (composite of termination, miscarriage, low birth weight or neonatal death) (adjusted OR 2.84 95% CI 1.66-4.87). Conclusion: Differences exist in phenotype, recovery of cardiac function and neonatal outcomes according to hypertensive status in women with PPCM